Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

The anti-CD38 antibody is an option for patients who have been treated with at least two prior therapies, including BMS’ Revlimid (lenalidomide) and a proteasome inhibitor such as Takeda’s

HTA guidance from NICE, the SMC and the AWMSG

Celgene has scored a positive recommendation from England’s cost-effectiveness watchdog NICE for Revlimid in follicular lymphoma, chalking up another indication.

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma The 750-patrient ELOQUENT-1 trial showed that adding Empliciti (elotuzumab) to background treatment with BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone didn’t extend the time patients with newly-diagnosed ... That said, “Empliciti,

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma Sarclisa will now be available for patients with relapsed or refractor multiple myeloma who have received at least two prior therapies, including Celgene’s Revlimid (lenalidomide) and a proteasome inhibitor.

Celgene’s Revlimid scores NICE approval in follicular lymphoma

Celgene’s Revlimid scores NICE approval in follicular lymphoma Celgene won European Commission approval for this Revlimid treatment regimen in follicular lymphoma back in December, on the back of results from its phase 3 AUGMENT study. ... Revlimid plus MabThera demonstrated a median progression-free survival rate

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics